Cancer Localization in the Prostate with F-18 Fluorocholine Position Emission Tomography
Final rept. 20 Dec 2006-19 Dec 2007
QUEEN'S MEDICAL CENTER HONOLULU HI
Pagination or Media Count:
The project evaluated fluorine-18 F-18 fluorocholine positron emission tomography PET as an imaging technique for delineating malignancy in the prostate gland The technique measures tissue metabolism of fluorncholine, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. Based on this measurement, it was proposed that cancerous tissue can be differentiated from benign tissue in the prostate. Project Scope Men with prostate cancer undergoing treatment with radical prostatectomy surgery were recruited for pre-operative PET scanning to measure fluorocholine uptake in the prostate gland. Imaging results were compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of prostate cancer sextant localization on the basis of measured fluorocholine uptake The data acquired thus far with conventional PET in 15 subjects 2 pilot subjects and 13 recruited by the study was summarized in the 2006 final report. Since then, the project scope has been modified to incorporate the use of PETCT and other new PET imaging technologies. A no-cost extension is being requested to continue the project using PETCT with the goal of accruing at least ten additional subjects. Additional immunohistochemical analyses are planned once additional prostate specimens have been collected To better facilitate this task, a method to establish spatial correspondence between histology slides and ex vivo MRl was developed this year to allow histological correspondence to be propagated to the in vivo imaging space. This latter project outcome should aid histopathologic correlations in future validation studies of fluorocholine PET and other prostate imaging techniques.
- Anatomy and Physiology
- Medicine and Medical Research